Tocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19

The authors urge clinicians to observe for early signs of CMV reactivation in patients presenting with gastrointestinal bleeding and intestinal perforation after receiving tocilizumab or other immunosuppressive therapy as a treatment for COVID 19. Early recognition of CMV infection and treatment wil...

Descripción completa

Detalles Bibliográficos
Autores principales: Khatib, Mohamad Y., Shaik, Karimulla S., Ahmed, Amna A., Alwraidat, Mohammad A., Mohamed, Ahmed S., Abou Kamar, Mohamad R., Sharaf Eldean, Mouhammad Z., Aldaraiseh, Bashar K., Nashwan, Abdulqadir J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813092/
https://www.ncbi.nlm.nih.gov/pubmed/33489151
http://dx.doi.org/10.1002/ccr3.3487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813092/
https://www.ncbi.nlm.nih.gov/pubmed/33489151
http://dx.doi.org/10.1002/ccr3.3487

Ejemplares similares